Solara Active Pharma Sciences Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3vg2gh8c83m5t13fee1ldxk7.pdf

Key Takeaways


Topline Recovery & Volume Dynamics

Purohit: "Q2 2024 is a turnaround quarter for Solara with improved capacity utilization."

Vizag: The Central Lever


Margin & Cost Structure

Purohit: "if I'm able to maintain the same gross margin and increase the revenue growth significantly that adds to absolute gross margin, you see a 30 crore, 40 crore of jump of gross margin which actually adds to the bottom line only."

Ibuprofen: Dependence & Strategy

Purohit: "Our objective would be to reduce the percentage of dependence while also increasing the market share in absolute terms. So, basically which means the other products also have to grow significantly"

Balance Sheet & Cash Flow

Purohit: "we should be able to announce the plan within this quarter only, but yes, I think it's on the fast track."

Operational Risks & Watchpoints

Purohit: "Our objective is to fix the fundamentals of the company and once the utilization goes up, once we have a better utilization of other products, when our market share increases all these things, we are taking all these measures together, so automatically it will be a function."

Guidance & Commitments

CommitmentSpecificsTimeline
Rights issue announcementPlan to be announcedWithin the current quarter (Q3 FY24)
Gross margin recoveryReturn to 50% historic level consistentlyNext 2–3 years
EBITDA margin targetReach higher-teens levelNo date; corrective steps underway
Ibuprofen demand stabilityStable in a range, based on customer discussionsNext 2–3 years
Revenue growth aspirationMid-teens revenue growth targetOver 2–3 years
Vizag full utilization (conservative case)₹50–60 crores minimum turnover increase, ₹20–30 crores margin additionNo date; "definitely doable on a conservative basis"
Debtors improvementGood improvement expectedNo date; function of business activities

Key Metrics

MetricQ2 FY24
Revenue₹426.4 cr, 20% QoQ and ~25% YoY growth
Gross margin44.3%, similar to Q2 FY23; value ₹189.1 cr, 25% YoY growth
EBITDA9.0%, 331 bps QoQ improvement; value ₹38.2 cr, 27% YoY growth
Revenue from regulated markets70% of total revenue
Gross debt₹972 cr as of Sep 30, reduced by ₹29 cr from Mar 23
Working capital₹811.5 cr, ~190 days, improved ~20 days over Mar 23
Vizag capacity utilization~50%, up from 20–25% previously
Vizag under recoveriesHalved in H1 FY24, down to ~₹10 cr from ~₹40 cr
Vizag revenue~₹33 cr in Q2, ~₹50–60 cr in H1 FY24
New products revenue contribution5–10% of total revenue
R&D market extensions filed11 filed for 10 existing products in H1 FY24
Other expenses YoY increase~₹20 cr, partly due to lower Vizag utilization earlier